Photo of Dr. Hagop Kantarjian from obroncology.com
Jul 22, 2023, 17:56
High response rates in poor-risk population – Hagop Kantarjian
Our study of aza + ven + pevonedistat NEDD8-activating enzyme inhibitor in secondary AML & MDS/CMML after HMA failure. High response rates in poor-risk population. Data from randomized ph3 study in AML are awaited.
For article: Click here
Source: Hagop Kantarjian/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 06:33
Nov 15, 2024, 05:57
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42